Resultados de la búsqueda 91-100 of 11463 for ESCITALOPRAM+OXALATE

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

3. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.

5. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to determine how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...